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Background: N-Myc downstream-regulated gene 2 (NDRG2), as a tumor suppressor, has been demonstrated to
inhibit tumor invasion and migration of hepatocellular carcinoma (HCC) by reducing the expression of CD24, which
has been identified as a prognostic factor for HCC patients. However, the clinical significance of combined NDRG2
and CD24 expression in HCC remains unclear. Thus, the aim of the current study was to investigate the relationship
of NDRG2 and CD24 expression with clinicopathological parameters and patients’ survival.
Methods: Immunohistochemistry was performed to detect the expression and subcellular localizations of NDRG2
and CD24 proteins in 130 pairs of HCC and adjacent nonneoplastic liver tissues.
Results: NDRG2 protein was strongly expressed in the cytoplasm and plasma membrane of hepatocytes in
adjacent nonneoplastic liver tissues, whereas its immunostaining was weak or negative in HCC tissues. In contrast,
CD24 protein exhibited the cytoplasm immunostaining in tumor cells of HCC tissues but showed negative
expression in adjacent nonneoplastic liver tissues. The statistical analysis also showed that the expression levels of
NDRG2 and CD24 proteins in HCC tissues were respectively lower and higher than those in adjacent nonneoplastic
liver tissues significantly (both P < 0.001). In addition, there was an inverse correlation between NDRG2 expression
and CD24 expression in HCC tissues (P = 0.02). Moreover, combined NDRG2 downregulation and CD24 upregulation
(NDRG2-low/CD24-high) more frequently occurred in HCC tissues with high serum AFP (P = 0.03), advanced tumor
stage (P = 0.001) and high tumor grade (P = 0.02). Furthermore, HCC patients with NDRG2-low/CD24-high expression
showed shortest 5-year disease-free survival and 5-year overall survival (both P < 0.001) of four groups (NDRG2-low/
CD24-high, NDRG2-low/CD24-low, NDRG2-high/CD24-high, NDRG2-high/CD24-low). Of note, the multivariate survival
analysis showed that the combined aberrant expression of NDRG2 and CD24 proteins was an independent prognostic
factor for both 5-year disease-free survival and 5-year overall survival (both P = 0.01) in HCC.
Conclusions: These findings suggest that the downregulation of NDRG2 combined with the upregulation of CD24
may play a synergistic role in the occurrence and progression of HCC. A combined detection of NDRG2/CD24
expression may benefit us in determining the prognosis in patients with HCC.
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Hepatocellular carcinoma (HCC), as one of the most
common malignancies in the developing countries, has
become the third leading cause of cancer-related deaths
globally [1]. The incidence of HCC is still increasing in
the developing countries. Annually, more than 700,000
new cases are diagnosed worldwide and also unfortunately
more than 600,000 deaths are attributed to this cancer [2].
HCC is highly lethal because of its aggressive metastasis
and an advanced stage at the time of diagnosis. The
five-year survival rate of this cancer is merely 7% [3].
Liver transplantation and surgical resection remain the
cornerstone of curative therapies, which can improve
the chances of survival of patients with HCC [4]. Since the
diagnosis at early stage of HCC offers the only hope for
curative therapies, it is of utmost importance to screen
high-risk patients effectively. With the increasing
understanding of tumor biology of HCC, recent studies
have identified more and more molecular markers with
high sensitivity and specificity for diagnosis and prognosis
in patients with HCC.
N-myc downstream-regulated gene 2 (NDRG2) belongs
to the NDRG family containing four members, NDRG1,
NDRG2, NDRG3 and NDRG4, the amino acid sequence
homology among which is 57-65%, suggesting the
conserved function of this family [5]. NDRG2 is localized
on chromosome 14q11.2 and encodes a protein of 41 kDa
weight [6]. Physiologically, it is involved in cell proliferation,
differentiation, and neurodegeneration, and is extensively
expressed in cells of the brain, the liver, the kidneys, the
salivary glands and muscles, but is almost undetectable in
the thymus, the bone marrow and leukocytes of peripheral
blood [7]. Under the pathological conditions, NDRG2
functions as a tumor suppressor gene and is down-
regulated in a variety of human cancer types, such as
glioblastoma, thyroid cancer, breast cancer, HCC, gastric
cancer, colorectal cancer and prostate cancer [8-14]. In
addition, it has been demonstrated to be implicated in the
process of apoptosis in response to DNA lesion, and acts
as an inhibitor of cellular proliferation. Several in vitro
studies showed a reduced cell growth when NDRG2 was
over-expressed in cell-lines lacking endogenous expression
[15]. Moreover, the upregulation of NDRG2 has been
found to be associated with a favorable prognosis in
several human malignancies, such as high-grade gliomas,
gastric cancer and HCC [16-18]. These findings suggest
that NDRG2 may play a crucial role in suppressing
carcinogenesis.
CD24, as a small heavily glycosylated mucin-like
glycosyl-phosphatidylinositol (GPI)-linked cell surface
protein, is attached to the cell membrane by a glycosyl-
phosphatidylinositol anchor [19]. It is not only expressed in
developing or regenerating tissue but also in granulocytes,
pre-B cells, keratinocytes, and renal tubules, and plays animportant roles in cell selection and maturation during
hematopoiesis [20]. Under the pathological conditions,
CD24, as a member of Ral GTPases signaling which
mediates the transformation, tumorigenesis, and tumor
progression, functions as a Ral-regulated target and is
involved in cell adhesion and tumor metastasis [21]. Its
upregulation has been observed not only in haematologic
malignancies, but also in various solid tumors, such as
glioma, nasopharyngeal carcinoma, breast cancer, small
cell lung carcinoma, HCC, renal cell carcinoma, ovarian
cancer, bladder carcinoma and prostate cancer [22-30].
The overexpression of CD24 is usually tied with a more
aggressive progression of tumor. More interestingly, it has
been identified as a novel prognostic marker in a variety
of human malignancies, suggesting its significant impact
on patient outcome.
Previous studies has reported that NDRG2 may reduce
the metastatic potential of cancer cells by regulating the
expression of CD24. Especially in HCC, Zheng et al.
[18] reported that NDRG2 expression was negatively
correlated with tumor malignancy and could inhibit
HCC cell adhesion, migration and invasion by regulating
the expression of CD24, which has been demonstrated by
Yang et al. [26] to be a novel predictor for poor prognosis
of HCC patients after surgery. However, the clinical
significance of combined expression of NDRG2 and
CD24 in HCC remains unclear. Thus, the aim of the
current study was to investigate the relationship of
NDRG2 and CD24 expression with clinicopathological
parameters and patients’ survival.
Methods
Patients and tissue samples
This study was approved by the Research Ethics
Committee of 302nd Hospital of PLA, Beijing, China.
Written informed consent was obtained from all of the
patients. All specimens were handled and made anonym-
ous according to the ethical and legal standards.
In this retrospective study, a total of 130 patients with
primary HCC who underwent a curative liver resection at
the 302nd Hospital of PLA, Beijing, China, were enrolled.
One hundred and thirty HCC and adjacent nonneoplastic
liver tissues obtained from these patients were retrieved
from the tissue bank of the Department of Pathology in
the 302nd Hospital of PLA. These patients were diagnosed
as HCC March 2001 and February 2006. None of the
patients recruited in this study had chemotherapy or
radiotherapy before the surgery. HCC diagnosis was
based on World Health Organization (WHO) criteria.
Tumor differentiation was defined according to the
Edmondson grading system. Liver function was assessed
using the Child-Pugh scoring system. Tumor staging was
determined according to the sixth edition of the tumor-
node-metastasis (TNM) classification of the International
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130 patients are summarized in Table 1.
The median follow-up period of 130 patients with
primary HCC was 8.6 years. Postoperative surveillance
included routine clinical and laboratory examinations
every third month, computed tomography scans of the
abdomen, and radiographs of the chest every third month.
After 5 years, the examination interval was extended to
12 months.
Immunohistochemistry analysis
Immunohistochemistry was performed to detect the
expression patterns and the subcellular localizations
of NDRG2 and CD24 proteins in HCC and adjacent
nonneoplastic liver tissues following the protocol of
our previous study [31-33]. The primary antibodies: mouse
anti-human NDRG2 monoclonal antibody (Neomarkers,




Case Male (N = 96) Female (n = 34)
Age (years)
≤50 72 52 20
>50 58 44 14
Serum AFP
Positive 72 54 18
Negative 58 42 16
Tumor stage
T1 23 19 4
T2 40 30 10
T3 52 37 15
T4 15 10 5
Tumor grade
G1 31 21 10
G2 76 57 19
G3 23 18 5
Growth pattern
Trabecular 101 76 25
Nontrabecular 29 20 9
Cirrhosis
Yes 86 63 23
No 44 33 11
Underlying liver disease
Alcoholic 25 16 9
Hepatitis B 49 39 10
Hepatitis C 35 26 9
Unknown 21 15 6dilution, Santa Cruz, CA, USA) and mouse anti-human
CD24 monoclonal antibody (Neomarkers, Clone 24C02,
1:100 dilution, Fremont, CA, US). The specificities of these
two primary antibodies have been validated by Gao et al.
[34] and Bircan et al. [35]. Secondary antibody for the
detection of primary antibody: anti-mouse IgG (#sc-2025,
Santa Cruz Biotechnology, Inc. USA). The negative controls
were processed in a similar manner with PBS instead
of primary antibody. The positive NDRG2 and CD24
expressions confirmed by western blotting were used
as positive controls for immunostaining.
The results of immunohistochemistry were evaluated
by two independent experienced pathologists, who were
blinded to the clinicopathological data and clinical
outcomes of the patients. Their scores were compared
and any discrepant scores were re-examined by both
pathologists to reach a consensus score. The number of
positive-staining cells in ten representative microscopic
fields was counted and the percentage of positive cells was
calculated. The percentage scoring of positive tumor cells
was as follows: 0 (0%), 1 (1-10%), 2 (11-50%) and 3
(>50%). The staining intensity was visually scored and
stratified as follows: 0 (negative), 1 (weak), 2 (moderate)
and 3 (strong). A final score was obtained for each case by
multiplying the percentage and the intensity score.
Therefore, tumors with a multiplied score exceeding
median of total score for NDRG2 (median = 2.39) or CD24
(median = 4.16) were deemed to be high expressions of
NDRG2 or CD24; all other scores were considered to be
low expressions of NDRG2 or CD24.
Statistical analysis
Statistical analysis was performed by the software of
SPSS version13.0 for Windows (SPSS Inc, IL, USA)
and SAS 9.1 (SAS Institute, Cary, NC). The differences in
the means of NDRG2 and CD24 expression levels
between HCC and adjacent nonneoplastic liver tissues
were determined using the paired t test. The chi-squared
test was used to show differences in categorical variables.
Correlations between CREB and pCREB expression were
calculated using Spearman’s correlation. The differences
in patient survival were determined by the Kaplan-Meier
method and the log-rank test, respectively. A Cox regres-
sion analysis (proportional hazard model) was per-
formed for the multivariate analyses of prognostic factors.
Differences were considered statistically significant when
P was less than 0.05.
Results
Expression patterns and subcellular localizations of
NDRG2 and CD24 in HCC and adjacent nonneoplastic
liver tissues
Expression patterns and subcellular localizations of
NDRG2 and CD24 proteins in 130 self pairs of HCC and
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observed by the immunohistochemistry analysis.
Representative images are shown in Figure 1. The
immunostainings of both NDRG2 and CD24 proteins
varied in the intensity and the percentage of positive
tumor cells. As shown in Figure 1A and B, NDRG2
protein was strongly expressed in the cytoplasm and
plasma membrane of hepatocytes in adjacent nonneoplastic
liver tissues, whereas its immunostaining was weak or
negative in HCC tissues. In contrast, CD24 protein
exhibited the cytoplasm immunostaining in tumor
cells of HCC tissues but showed negative expression
in adjacent nonneoplastic liver tissues (Figure 1D and E).
The statistical analysis also showed that the expression
levels of NDRG2 and CD24 proteins in HCC tissues were
respectively lower and higher than those in adjacent
nonneoplastic liver tissues significantly (both P < 0.001,
Figure 1C and F).
In addition, based on the scoring system used in the
present study, 30 (23.08%) cases were both high expression
of NDRG2 and CD24, 28 (21.54%) cases were both low
expression of NDRG2 and CD24, 22 (16.92%) cases were
NDRG2-high and CD24-low expression, and 50 (38.46%)
cases were NDRG2-low and CD24-high expression.
Moreover, there was an inverse correlation betweenFigure 1 Expression patterns and subcellular localizations of NDRG2
tissues. Representative immunohistochemistry images respectively for NDR
nonneoplastic liver tissues (Original magnification × 200). Statistical analysis sh
tissues were respectively lower and higher than those in adjacent nonneoplaNDRG2 expression and CD24 expression in HCC tissues
(r = 0.45, P = 0.02, Figure 2).
Association between combined aberrant expression of
NDRG2 and CD24 and the clinicopathological
characteristics of HCC
The association between combined aberrant expression of
NDRG2 and CD24 (NDRG2/CD24) and the clinicopatho-
logical characteristics of patients with HCC was summa-
rized in Table 2. Combined NDRG2 downregulation
and CD24 upregulation (NDRG2-low/CD24-high) more
frequently occurred in HCC tissues with high serum
AFP (P = 0.03), advanced tumor stage (P = 0.001) and
high tumor grade (P = 0.02).
Prognostic implications of combined aberrant expression
of NDRG2 and CD24 in HCC
Five-year disease-free survival was observed in 30 (23.08%)
patients, whereas in 100 (76.92%) patients, disease recurred,
and 88 (67.69%) even died during a 5-year follow-up period.
The association between combined aberrant expression of
NDRG2 and CD24 (NDRG2/CD24) and the survival
rates were tested by the method of Kaplan-Meier. The
Chi-square value by Log Rank (Mantel-Cox) indicated a
significant difference among different groups with regardand CD24 proteins in HCC and adjacent nonneoplastic liver
G2 (A and B) and CD24 (D and E) proteins in HCC and adjacent
owed that the expression levels of NDRG2 and CD24 proteins in HCC
stic liver tissues significantly (both P < 0.001, C and F, respectively).
Figure 2 Scatter diagram of immunoreactive scores of NDRG2
and CD24 proteins in HCC tissues. As determined by Spearman’s
correlation, there was an inverse correlation between NDRG2
expression and CD24 expression in HCC tissues (P = 0.02).
Table 2 Association of the combined aberrant expression
of NDRG2 and CD24 proteins with clinicopathological




Case NDRG2-low/CD24-high (n, %) P
Age (years)
≤50 72 28 (38.89) NS
>50 58 22 (37.93)
Gender
Male 96 35 (36.46) NS
Female 34 15 (44.12)
Serum AFP
Positive 72 34 (47.22) 0.03
Negative 58 16 (27.59)
Tumor stage
T1 23 0 (0) 0.001
T2 40 10 (25.00)
T3 52 25 (48.08)
T4 15 15 (100.00)
Tumor grade
G1 31 5 (16.13) 0.02
G2 76 30 (39.47)
G3 23 15 (65.22)
Growth pattern
Trabecular 101 40 (39.60) NS
Nontrabecular 29 10 (34.48)
Cirrhosis
Yes 86 35 (40.70) NS
No 44 15 (34.09)
Underlying liver disease
Alcoholic 25 10 (40.00) NS
Hepatitis B 49 20 (40.82)
Hepatitis C 35 10 (28.57)
Unknown 21 10 (47.62)
Note: ‘NS’ refers to the differences among groups have no statistical significance.
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(Figure 3A and B). The results by pairwise comparisons
showed that the statistically significant difference of
disease-free survival and overall survival existed between
NDRG2-low/CD24-high patients and any of other three
groups (both P < 0.001). In all four groups, NDRG2-low/
CD24-high patients had the poorest prognosis.
Furthermore, in a multivariate Cox model, including
serum AFP, tumor stage, tumor grade, presence of
cirrhosis, and NDRG2/CD24 expression, we found that
tumor stage (P = 0.009 and 0.01, respectively, Table 3) and
NDRG2/CD24 expression (both P = 0.01, Table 3) were
independent poor prognostic factors for both 5-year
disease-free survival and 5-year overall survival in HCC.
Discussion
It is of great challenge for clinicians and basic scientists
to find out the molecular markers associated with the
progression and prognosis of HCC. In the current study,
the clinical significance of combined aberrant expression
of NDRG2 and CD24 in HCC was evaluated.
Tumor progression and metastasis of HCC are a multi-
step process including cell adhesion to the extracellular
matrix (ECM), proteolytic digestion of ECM, invasion into
the lymph and blood vessels, and migration [36]. NDRG2
has been identified as one of tumor suppressor genes in the
mechanism of metastasis formation. An increasing number
of studies have performed to analyze the expression levels
of NDRG2 in various neoplasms. Zhao et al. [9] revealed a
decrease of NDRG2 expression in thyroid carcinomas.
Deng et al. [8] indicated that the reduced NDRG2 expres-
sion in approximately 60% of gliomas versus the expression
levels in normal brain tissue. Liang et al. [10] reported that
the lack of NDRG2 might be associated with oncogenicproperties through the loss of its role as a tumor suppres-
sor, and that NDRG2 was an independent poor prog-
nostic factor predicting survival in renal cell carcinoma.
Lorentzen et al. [11] found that the expression of NDRG2
mRNA was reduced in breast cancer. Especially in HCC,
Zheng et al. [18] observed the downregulation of NDRG2
which can inhibit ECM–based, Rho-driven tumor cell
invasion and migration and thereby play important roles
in suppressing tumor metastasis according to the data of
Lee et al. [12]. Consistent with these findings, we in the
current study also confirmed the reduced expression
of NDRG2 at protein level in HCC tissues compared
Figure 3 Kaplan-Meier disease-free survival (A) and overall survival (B) curves for 4 groups of NDRG2 and CD24 expression in HCC
tissues. Patients with NDRG2-low/CD24-high expression profile had the worst outcome for both disease-free survival and overall survival among
the 4 groups. Pairwise comparisons showed that the statistically significant difference of survival rates existed between NDRG2-low/CD24-high
cases and any of other three groups. Note: ‘a’ refers to NDRG2-high/CD24-low; ‘b’ refers to NDRG2-low/CD24-low and NDRG2-high/CD24-high;
‘c’ refers to NDRG2-low/CD24-high.
Li et al. Diagnostic Pathology 2014, 19:209 Page 6 of 8
http://www.diagnosticpathology.org/content/19/1/209with adjacent nonneoplastic liver tissues, suggesting
its implication in the tumorigenesis of HCC.
During the process of tumor metastasis, it is of
particular importance to induce tumor cells to bind
with platelets in the blood stream. The enhancement
of the ability of tumor to bind to endothelial cells
may also be beneficial for metastasis [37]. Because it has
been identified as a ligand of P-selectin, an adhesion
receptor on activated endothelial cells and platelets,
CD24 functionally enhances the metastatic potential
of malignant-cells. Kim et al. [24] demonstrated that
CD24 expression was a significant predictor of distant
metastasis for patients undergoing curative resection
followed by adjuvant chemoradiotherapy especially for
node-positive extrahepatic bile duct cancer. Takahashi et al.
[25] indicated that the overexpression of CD24 was
markedly associated with lymph node metastasis of
gastric cancer. Thomas et al. [27] identified CD24 as
an effector of HIF-1-driven primary tumor growth
and metastasis. Zhu et al. [28] also determined the
overexpression of CD24 as an independent factor associ-
ated with tumor metastasis of epithelial ovarian cancer.
Especially in HCC, Yang et al. [26] found that CD24 was
overexpressed in the highly metastatic HCC cell line and
in tumor tissues of patients with recurrent tumors. TheyTable 3 Multivariate survival analysis of five-year overall and
carcinoma
Features Five-year overall survival
HR 95% CI
Serum AFP 1.931 0.685-4.056
Tumor stage 2.879 1.366-5.196
Tumor grade 1.563 0.609-4.088
Presence of cirrhosis 1.919 0.738-4.102
NDRG2/CD24 expression 5.916 1.363-12.698also revealed that CD24 was a significant predictor for
overall survival and relapse-free survival. CD24 expression
was correlated with poor prognosis independent of
α-fetoprotein, tumor-node-metastasis stage, and Edmondson
stage. In line with these findings, our data showed
the upregulation of CD24 in HCC tissues compared with
adjacent nonneoplastic liver tissues, implying that CD24
may play a role in the development of HCC.
Since the recent studies have found the regulatory
effect of NDRG2 on CD24 in several cancer cells, we
hypothesized that the combined aberrant expression
of NDRG2 and CD24 might be associated with tumor
progression and prognosis in patients with HCC.
Interestingly, our data validated this hypothesis. We
found that the combined NDRG2 downregulation and
CD24 upregulation was markedly associated with the
aggressive clinicopathological characteristics of HCC,
including serum AFP level, tumor stage and tumor
grade. More importantly, we analyzed the association of
NDRG2/CD24 conjoined expression with the prognosis of
HCC. Significant difference of prognosis was found among
four different statuses of NDRG2/CD24 co-expression.
The patients with NDRG2-high/CD24-low had the best
outcome, while the NDRG2-low/CD24-high had the worst.
Multivariate analysis revealed that the NDRG2/CD24disease-free survival in 130 patients with hepatocellular
Five-year disease-free survival
P HR 95% CI P
0.063 1.953 0.615-4.273 0.062
0.009 2.686 1.386-6.009 0.01
0.081 1.551 0.607-4.466 0.086
0.063 1.921 0.793-4.219 0.062
0.01 5.268 1.256-11.088 0.01
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indicator for both disease-free survival and overall
survival of patients with HCC. Further investigation
extended in much more cases is in need to evaluate the
potential application value of NDRG2/CD24 co-expression
as dependent or independent prognosis factor of HCC in
clinical setting.
Conclusion
In conclusion, our data in the current study suggest
that the downregulation of NDRG2 combined with
the upregulation of CD24 may play a synergistic role in
the occurrence and progression of HCC. A combined
detection of NDRG2/CD24 expression may benefit us in
determining the prognosis in patients with HCC.
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